Program
annamycin
Also written as “Liposomal Annamycin”, “Liposomal Annamycin Injection in combination with Cytarabine Injection” and “Liposomal Annamycin for Injection in combination with Cytarabine Injection.”.
Its studies are mostly in Leukemia, Myeloid, Acute · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Sarcoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moleculin Biotech | 51 open or running | phase 3since Dec 5, 2024 | Oct 16, 2017 | Aug 2029phase 3 · NCT06788756 |
| Callisto Pharmaceuticals | 20 open or running | phase 2since Dec 29, 2005 | Dec 29, 2005 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 29, 2005First study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNew to Callisto PharmaceuticalsCallisto Pharmaceuticals · NCT00271063 · 34 enrolled · United States
- Jan 30, 2007Phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaCallisto Pharmaceuticals · NCT00430443 · 3 enrolled · United States
- Oct 16, 2017Moleculin Biotech's first study: phase 2 study in Leukemia, Myeloid, AcuteNew to Moleculin BiotechMoleculin Biotech · NCT03315039 · 7 enrolled · United States
- Dec 25, 2017Phase 2 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT03388749 · 20 enrolled · Poland
- May 4, 2021Phase 2 study in SarcomaMoleculin Biotech · NCT04887298 · 36 enrolled · United States
- Feb 22, 2022Phase 2 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT05319587 · 22 enrolled · Italy, Poland
- Dec 5, 2024Phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756 · 312 planned · United States, Czechia, Georgia and more
Ahead
- Aug 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06788756Leukemia, Myeloid, Acute · United States, Czechia, Georgia and more | 3 | Recruiting | Moleculin Biotech | Aug 2029 | 312 |
| NCT05319587Leukemia, Myeloid, Acute · Italy, Poland | 2 | Completed | Moleculin Biotech | Aug 2, 2023 | 22 |
| NCT04887298Sarcoma · United States | 2 | Completed | Moleculin Biotech | Sep 29, 2022 | 36 |
| NCT03388749Leukemia, Myeloid, Acute · Poland | 2 | Completed | Moleculin Biotech | Feb 8, 2022 | 20 |
| NCT03315039Leukemia, Myeloid, Acute · United States | 2 | Completed | Moleculin Biotech | Jan 14, 2020 | 7 |
| NCT00430443Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States | 1 | Terminated | Callisto Pharmaceuticals | 3 | |
| NCT00271063Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States | 2 | UNKNOWN | Callisto Pharmaceuticals | 34 |
How it is read
Names in the registry
- “Liposomal Annamycin”, 5 entries
- “Liposomal Annamycin Injection in combination with Cytarabine Injection”, 2 entries
- “Liposomal Annamycin for Injection in combination with Cytarabine Injection.”, 1 entry
- “Liposomal Annamycin (L-Annamycin)”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 4 studies
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 2 studies
- Sarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.